CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
Rhea-AI Summary
CRISPR Therapeutics (Nasdaq: CRSP) announced its senior management will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026 at 1:40 p.m. PDT. A live webcast will be available on the company's Investors "Events & Presentations" page, with a replay archived for 14 days.
Positive
- None.
Negative
- None.
News Market Reaction – CRSP
In the May 6 session, CRSP gained 5.15%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 04 | Q1 2026 earnings | Neutral | -2.2% | Reported Q1 2026 results, CASGEVY revenue, cash of $2.44B, ongoing losses. |
| Apr 07 | Conference appearance | Neutral | +1.1% | Announced Needham healthcare conference presentation and webcast details. |
| Mar 11 | Upsized note offering | Negative | -5.4% | Priced upsized $550M 2031 convertible notes plus $50M option. |
| Mar 10 | Proposed note deal | Negative | -10.2% | Proposed $350M 2031 convertible notes with $52.5M option for corporate use. |
| Feb 12 | FY25 earnings | Positive | +8.5% | Reported Q4 and 2025 results with CASGEVY revenue and pipeline progress. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Convertible note offerings have coincided with negative moves, while earnings and business updates have more often aligned with positive or moderate reactions.
Over the last few months, CRISPR Therapeutics reported Q4 2025 and Q1 2026 results, highlighting CASGEVY revenues ($54M in Q4, $116M for 2025, and $43.0M in Q1 2026) and a strong cash position of about $2.44B. Two March 2026 announcements covered a proposed and then upsized 2031 convertible senior notes offering, which saw negative price reactions. A prior Needham conference presentation drew a modestly positive move. Today’s Bank of America conference appearance fits this pattern of regular investor outreach between major financial and pipeline milestones.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026 1:40 p.m. PDT.
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase™ editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
